loading
전일 마감가:
$5.74
열려 있는:
$5.79
하루 거래량:
73,569
Relative Volume:
0.85
시가총액:
$36.78M
수익:
$5.75M
순이익/손실:
$-38.96M
주가수익비율:
-0.4571
EPS:
-12.47
순현금흐름:
$-32.63M
1주 성능:
+0.00%
1개월 성능:
+41.09%
6개월 성능:
-25.78%
1년 성능:
-15.68%
1일 변동 폭
Value
$5.64
$5.9256
1주일 범위
Value
$5.39
$6.30
52주 변동 폭
Value
$2.92
$11.20

칼라 파마슈티컬스 Stock (KALA) Company Profile

Name
명칭
Kala Bio Inc
Name
전화
781-996-5252
Name
주소
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Name
직원
38
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
KALA's Discussions on Twitter

KALA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
KALA
Kala Bio Inc
5.70 36.78M 5.75M -38.96M -32.63M -12.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

칼라 파마슈티컬스 Stock (KALA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-11 개시 Ladenburg Thalmann Buy
2022-03-30 다운그레이드 JP Morgan Neutral → Underweight
2021-08-06 다운그레이드 JP Morgan Overweight → Neutral
2020-09-14 다운그레이드 Jefferies Buy → Hold
2020-07-23 개시 Northland Capital Outperform
2020-06-01 재개 Oppenheimer Outperform
2020-05-27 재확인 H.C. Wainwright Buy
2020-03-09 업그레이드 BofA/Merrill Neutral → Buy
2019-12-17 다운그레이드 BofA/Merrill Buy → Neutral
2019-03-14 개시 Jefferies Buy
모두보기

칼라 파마슈티컬스 주식(KALA)의 최신 뉴스

pulisher
Jul 21, 2025

What analysts say about KALA BIO Inc. stockRapid growth opportunities - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

KALA BIO Inc. Stock Analysis and ForecastJaw-dropping returns - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Is KALA BIO Inc. a good long term investmentUnmatched profit growth - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

KALA BIO (NASDAQ:KALA) Downgraded to “Sell” Rating by Wall Street Zen - Defense World

Jul 20, 2025
pulisher
Jul 15, 2025

What makes KALA BIO Inc. stock price move sharplyHigh Return Conservative Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why KALA BIO Inc. stock attracts strong analyst attentionMomentum Buy Alert - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How KALA BIO Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

All Eyes On KALA's CHASEWill The PCED Trial Make Its Case? - RTTNews

Jul 14, 2025
pulisher
Jul 13, 2025

LADENBURG THALM/SH SH Initiates Coverage on KALA BIO (NASDAQ:KALA) - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

KALA Bio completes enrollment of CHASE clinical trial - Ophthalmology Times

Jul 12, 2025
pulisher
Jul 12, 2025

KALA BIO (NASDAQ:KALA) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Jul 11, 2025
pulisher
Jul 11, 2025

Ladenburg Thalmann Initiates KALA BIO at Buy With $12 Price Target - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg | KALA Stock News - GuruFocus

Jul 11, 2025
pulisher
Jul 10, 2025

Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg - GuruFocus

Jul 10, 2025
pulisher
Jul 09, 2025

Kala Bio Announces Completion of Enrollment in Chase Clinical Trial Evaluating Kpi-012 for the Treatment of Persistent Corneal Epithelial Defect - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

KALA Completes Patient Enrollment in Phase 2b CHASE Trial for KP - GuruFocus

Jul 09, 2025
pulisher
Jul 09, 2025

Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

Kala Bio completes enrollment in Phase 2b trial for KPI-012 in eye disorder - Investing.com

Jul 09, 2025
pulisher
Jul 09, 2025

KALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial for KPI-012, Anticipates Topline Results by Q3 2025 - Quiver Quantitative

Jul 09, 2025
pulisher
Jul 09, 2025

KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire

Jul 09, 2025
pulisher
Jul 09, 2025

KALA BIO Eyes 100,000 Patient Market as Pivotal PCED Trial Completes Enrollment, Q3 Results Ahead - Stock Titan

Jul 09, 2025
pulisher
Jul 07, 2025

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discu - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - Yahoo Finance

Jul 07, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Purchases 17,130 Shares of HBT Financial, Inc. (NASDAQ:HBT) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Decreases Stake in KALA BIO, Inc. (NASDAQ:KALA) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Nexa Resources S.A. (NYSE:NEXA) Shares Sold by Millennium Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

24,353 Shares in T. Rowe Price Floating Rate ETF (NYSEARCA:TFLR) Acquired by Bank of America Corp DE - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Cadre Holdings, Inc. (NYSE:CDRE) Shares Acquired by Millennium Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Acquires 2,612 Shares of First Trust Indxx Global Natural Resources Income ETF (NASDAQ:FTRI) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Sells 1,791 Shares of Bluerock Homes Trust, Inc. (NYSEAMERICAN:BHM) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Buys 11,012 Shares of Liberty All-Star Growth Fund, Inc. (NYSE:ASG) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Kala Bio director Mark Iwicki sells $40,638 in stock By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Kala Bio director Mark Iwicki sells $40,638 in stock - Investing.com India

Jun 05, 2025
pulisher
Jun 04, 2025

KALA BIO Executives Sell Shares - TradingView

Jun 04, 2025
pulisher
Jun 04, 2025

Pre-market Movers: STSS, SGMT, NIVF, OGEN... - RTTNews

Jun 04, 2025
pulisher
Jun 03, 2025

KALA BIO (NASDAQ:KALA) Given “Outperform” Rating at Oppenheimer - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

KALA: Oppenheimer Announces Outperform Rating for Kala Bio | KALA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

KALA Stock Gains Momentum with Oppenheimer's Positive Outlook | - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

KALA Stock Gains Momentum with Oppenheimer's Positive Outlook | KALA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

Tidal Investments LLC Has $269,000 Stake in Air Lease Co. (NYSE:AL) - Defense World

Jun 01, 2025
pulisher
Jun 01, 2025

Aegon Ltd. (NYSE:AEG) Shares Sold by Millennium Management LLC - Defense World

Jun 01, 2025
pulisher
May 29, 2025

KALA BIO to Present at Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 29, 2025

KALA BIO to Reveal Latest Eye Disease Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan

May 29, 2025
pulisher
May 26, 2025

Q1 Earnings Estimate for KALA BIO Issued By HC Wainwright - Defense World

May 26, 2025
pulisher
May 25, 2025

HC Wainwright Lowers KALA BIO (NASDAQ:KALA) Price Target to $12.00 - Defense World

May 25, 2025

칼라 파마슈티컬스 (KALA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

칼라 파마슈티컬스 주식 (KALA) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Reumuth Mary
CHIEF FINANCIAL OFFICER
Jun 24 '25
Sale
4.01
3,631
14,560
62,100
Bazemore Todd
SEE REMARKS
Jun 24 '25
Sale
4.01
4,058
16,273
83,699
Brazzell Romulus K
SEE REMARKS
Jun 24 '25
Sale
4.01
5,251
21,057
82,698
Iwicki Mark T
Director
Jun 24 '25
Sale
4.01
13,227
53,040
258,433
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):